Gilead to face HIV antitrust claims

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead pays $1.25bn to GSK in HIV drug settlement

3 February 2022 Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents.

Americas

US govt argues Gilead’s patent claims are ‘insufficient’

19 May 2020 The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.

Americas

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Gilead to face HIV antitrust claims

More on this story

Editor's picks

Editor's picks

More features